Cargando…

Development of Nafamostat Mesylate Immediate-Release Tablet by Drug Repositioning Using Quality-by-Design Approach

We aimed to develop nafamostat mesylate immediate-release tablets for the treatment of COVID-19 through drug repositioning studies of nafamostat mesylate injection. Nafamostat mesylate is a serine protease inhibitor known to inhibit the activity of the transmembrane protease, serine 2 enzyme that af...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Hyeon-A, Kim, Joo-Eun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9228348/ https://www.ncbi.nlm.nih.gov/pubmed/35745792 http://dx.doi.org/10.3390/pharmaceutics14061219

Ejemplares similares

Fatal anaphylaxis Due to Nafamostat Mesylate During Hemodialysis
por: Kim, Joo-Hee, et al.
Publicado: (2021)

Quality by Design Applied Development of Immediate-Release Rabeprazole Sodium Dry-Coated Tablet
por: Lee, Sang-Ho, et al.
Publicado: (2021)

Nafamostat mesylate attenuates the pathophysiologic sequelae of neurovascular ischemia
por: Ghali, George Zaki, et al.
Publicado: (2020)

Cardiopulmonary arrest caused by nafamostat mesylate during hemodialysis
por: Shioya, Nobuki, et al.
Publicado: (2022)

Retraction: Nafamostat mesylate attenuates the pathophysiologic sequelae of neurovascular ischemia
Publicado: (2021)

Cytokine expressions of spinal cord injury treated by neurotropin and nafamostat mesylate
por: Sun, Chao, et al.
Publicado: (2021)

Synthesis of Celecoxib-Eutectic Mixture Particles via Supercritical CO(2) Process and Celecoxib Immediate Release Tablet Formulation by Quality by Design Approach
por: Hong, Seung-Hyeon, et al.
Publicado: (2022)

Adverse events associated with nafamostat mesylate and favipiravir treatment in COVID-19 patients
por: Hifumi, Toru, et al.
Publicado: (2020)

Dynamic changes in fibrinogen and D-dimer levels in COVID-19 patients on nafamostat mesylate
por: Osawa, Itsuki, et al.
Publicado: (2020)

Nafamostat Mesylate for Treatment of COVID-19 in Hospitalised Patients: A Structured, Narrative Review
por: Hernández-Mitre, María Patricia, et al.
Publicado: (2022)

Application of nafamostat mesylate for anticoagulation in hemoperfusion therapy in patients with bromadiolone poisoning: Case reports
por: Qian, Weiwei, et al.
Publicado: (2023)

Nafamostat mesylate-induced hyperkalemia in critically ill patients with COVID-19: Four case reports
por: Okajima, Masaki, et al.
Publicado: (2020)

Clinical efficacy of Nafamostat Mesylate in combination with Favipiravir for COVID-19 pneumonia treatment review article
por: Abduljabbar, Maram H.
Publicado: (2021)

Anaphylactic Reactions Caused by Nafamostat Mesylate during Hemodialysis before Surgery for Carpal Tunnel Syndrome
por: Nakamura, Yuta, et al.
Publicado: (2021)

Nafamostat mesylate prevents metastasis and dissemination of neuroblastoma through vascular endothelial growth factor inhibition
por: Morimoto, Mari, et al.
Publicado: (2022)

AN69ST membranes adsorb nafamostat mesylate and affect the management of anticoagulant therapy: a retrospective study
por: Hirayama, Takahiro, et al.
Publicado: (2017)

Nafamostat mesylate treatment in combination with favipiravir for patients critically ill with Covid-19: a case series
por: Doi, Kent, et al.
Publicado: (2020)

Nafamostat Mesylate Blocks Activation of SARS-CoV-2: New Treatment Option for COVID-19
por: Hoffmann, Markus, et al.
Publicado: (2020)

Identification of impurities in nafamostat mesylate using HPLC-IT-TOF/MS: A series of double-charged ions
por: Zhang, Yuxin, et al.
Publicado: (2020)

The Molecular Aspect of Antitumor Effects of Protease Inhibitor Nafamostat Mesylate and Its Role in Potential Clinical Applications
por: Chen, Xi, et al.
Publicado: (2019)

Unfractionated heparin versus nafamostat mesylate for anticoagulation during continuous kidney replacement therapy: an observational study
por: Kameda, Shinya, et al.
Publicado: (2023)

Inhibition of Listeria Monocytogenes HtrA Protease with Camostat, Gabexate and Nafamostat Mesylates and the Binding Mode of the Inhibitors
por: C, Amrutha M, et al.
Publicado: (2023)

Impact of Tablet Shape on Drug Dissolution Rate Through Immediate Released Tablets
por: Molavi, Fatima, et al.
Publicado: (2020)

Co-Spray Dried Nafamostat Mesylate with Lecithin and Mannitol as Respirable Microparticles for Targeted Pulmonary Delivery: Pharmacokinetics and Lung Distribution in Rats
por: Kang, Ji-Hyun, et al.
Publicado: (2021)

Effect of Excipients on the Quality of Drug Formulation and Immediate Release of Generic Metformin HCl Tablets
por: Arafat, Mosab, et al.
Publicado: (2023)

Nafamostat mesylate, a serine protease inhibitor, demonstrates novel antimicrobial properties and effectiveness in Chlamydia-induced arthritis
por: Inman, Robert D, et al.
Publicado: (2012)

Treatment effect of nafamostat mesylate in patients with COVID-19 pneumonia: study protocol for a randomized controlled trial
por: Moon, Kyunglan, et al.
Publicado: (2021)

Association between Nafamostat Mesylate and In-Hospital Mortality in Patients with Coronavirus Disease 2019: A Multicenter Observational Study
por: Inokuchi, Ryota, et al.
Publicado: (2021)

Correction: Unfractionated heparin versus nafamostat mesylate for anticoagulation during continuous kidney replacement therapy: an observational study
por: Kameda, Shinya, et al.
Publicado: (2023)

Formulation and In Vitro, In Vivo Evaluation of Effervescent Floating Sustained-Release Imatinib Mesylate Tablet
por: Kadivar, Ali, et al.
Publicado: (2015)

Determination of Doxazosin Mesylate in Tablets by RP-HPLC
por: Dhanya, B., et al.
Publicado: (2011)

Clinical improvement in a patient with severe coronavirus disease 2019 after administration of hydroxychloroquine and continuous hemodiafiltlation with nafamostat mesylate
por: Iwasaka, Sho, et al.
Publicado: (2020)

Nafamostat mesylate overcomes endocrine resistance of breast cancer through epigenetic regulation of CDK4 and CDK6 expression
por: Lin, Yueh-Te, et al.
Publicado: (2021)

Integration of transcriptomics and metabolomics reveals the molecular mechanisms underlying the effect of nafamostat mesylate on rhabdomyolysis-induced acute kidney injury
por: Guo, Wenli, et al.
Publicado: (2022)

Multivariate Design of 3D Printed Immediate-Release Tablets with Liquid Crystal-Forming Drug—Itraconazole
por: Jamróz, Witold, et al.
Publicado: (2020)

Evaluation of the effects of food on levodropropizine controlled-release tablet and its pharmacokinetic profile in comparison to that of immediate-release tablet
por: Lee, Soyoung, et al.
Publicado: (2018)

Correction: Formulation and In Vitro, In Vivo Evaluation of Effervescent Floating Sustained-Release Imatinib Mesylate Tablet
Publicado: (2022)

Nafamostat Mesylate Improved Survival Outcomes of Sepsis Patients Who Underwent Blood Purification: A Nationwide Registry Study in Japan
por: Kamijo, Hiroshi, et al.
Publicado: (2020)

Cardiac arrest caused by nafamostat mesilate
por: Kim, Hyo Shik, et al.
Publicado: (2016)

Apatinib mesylate tablet in the treatment of advanced malignant melanoma
por: Yang, Lingge, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_9u9c1tg4e784380mpa7mod0miu